BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pan LH, Zhao C, Ma YL. Is Y90 Radioembolization Superior or Comparable to Transarterial Chemoembolization for Treating Hepatocellular Carcinoma? Gastroenterology 2017;152:1627-8. [PMID: 28384449 DOI: 10.1053/j.gastro.2016.10.048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Li R, Xu T, Wang H, Wu N, Liu F, Jia X, Mi J, Lv J, Gao H. Dysregulation of the miR-325-3p/DPAGT1 axis supports HBV-positive HCC chemoresistance. Biochem Biophys Res Commun 2019;519:358-65. [PMID: 31519321 DOI: 10.1016/j.bbrc.2019.08.116] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
2 Ma X, Wang J, Zhuang J, Ma X, Zheng N, Song Y, Xia W. P4HB modulates epithelial-mesenchymal transition and the β-catenin/Snail pathway influencing chemoresistance in liver cancer cells. Oncol Lett 2020;20:257-65. [PMID: 32565952 DOI: 10.3892/ol.2020.11569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Chen M, Wu L, Tu J, Zhao Z, Fan X, Mao J, Weng Q, Wu X, Huang L, Xu M, Ji J. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression. EBioMedicine 2018;35:142-54. [PMID: 30111512 DOI: 10.1016/j.ebiom.2018.08.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]